Treatment of hodgkin lymphoma using an anti-pd-1 antibody
AssigneeBristol-Myers Squibb Company
InventorBenedetto FARSACI
Life of this patent
Estimating the term…
Abstract
This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
Claims15
A monoclonal antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 receptor (PD-1) (“anti-PD-1 antibody”) for use in a method of treating a subject afflicted with a tumor derived from a Hodgkin lymphoma, wherein the subject is administered a therapeutically effective amount of the anti-PD-1 antibody, wherein the subject was not responsive to a prior treatment selected from (i) an autologous stem cell therapy, (ii) brentuximab vedotin, and both (i) and (ii).
The anti-PD-1 antibody for use according to any one of claims 1 to 14, wherein the subject exhibits an overall survival of at least about one month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about one year, at least about eighteen months, at least about two years, at least about three years, at least about four years, or at least about five years after the initial administration.
Dependencies are inferred from the claim text.